Denavir is a drug owned by Mylan Pharmaceuticals Inc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 17, 2020. Details of Denavir's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6579981 | Antiviral guanine derivatives |
Jun, 2020
(4 years ago) |
Expired
|
| US6469015 | Pharmaceutical formulation |
Oct, 2019
(5 years ago) |
Expired
|
| US5916893 | Treatment of a latent infection of herpes virus |
Sep, 2015
(9 years ago) |
Expired
|
| US5840763 | Treatment of a latent infection of herpes viruses |
Sep, 2015
(9 years ago) |
Expired
|
| US6124304 | Penciclovir for the treatment of zoster associated pain |
Oct, 2014
(10 years ago) |
Expired
|
| US5866581 | Penciclovir for the treatment of post therapeutic neuralgia |
Oct, 2014
(10 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Denavir and ongoing litigations to help you estimate the early arrival of Denavir generic.
Denavir's Litigations
Denavir been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 14, 2000, against patent number US6579981. The petitioner , challenged the validity of this patent, with JARVEST et al as the respondent. Click below to track the latest information on how companies are challenging Denavir's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6579981 | January, 2000 |
Decision
(26 Sep, 2002) | JARVEST et al | |
| US6579981 | January, 2000 |
Decision
(04 Jul, 1776) | JARVEST et al | |
US patents provide insights into the exclusivity only within the United States, but Denavir is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Denavir's family patents as well as insights into ongoing legal events on those patents.
Denavir's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Denavir's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 17, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Denavir Generic API suppliers:
Penciclovir is the generic name for the brand Denavir. 3 different companies have already filed for the generic of Denavir, with Padagis Israel having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Denavir's generic
About Denavir
Denavir is a drug owned by Mylan Pharmaceuticals Inc. It is used for treating recurrent herpes labialis (cold sores) in adults. Denavir uses Penciclovir as an active ingredient. Denavir was launched by Mylan in 1996.
Approval Date:
Denavir was approved by FDA for market use on 24 September, 1996.
Active Ingredient:
Denavir uses Penciclovir as the active ingredient. Check out other Drugs and Companies using Penciclovir ingredient
Treatment:
Denavir is used for treating recurrent herpes labialis (cold sores) in adults.
Dosage:
Denavir is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% | CREAM | Prescription | TOPICAL |